ASH 2023 | Myeloma and AL amyloidosis updatesAL amyloidosis, Conferences, MPE, MyelomaDecember 15, 2023
MPE launches a report focused on the impact of AL amyloidosis in quality of lifeAL amyloidosis, MPENovember 21, 2023
Sign up for the MPE webinar on EHA myeloma and AL amyloidosis highlights AL amyloidosis, Conferences, MPE, MyelomaJune 14, 2023
MPE launches the Myeloma and AL Amyloidosis European Clinical Trial NavigatorAccess, AL amyloidosis, MPE, MyelomaApril 23, 2024
EHA 2020 – Subcutaneous daratumumab shows improved clinical outcomes in AL amyloidosisAL amyloidosisJune 14, 2020
ASCO and EHA highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, Myeloma, VideosJuly 20, 2020
ASH 2020 | Data on Real World Evidence (RWE) on AL amyloidosisAL amyloidosis, ConferencesDecember 10, 2020
Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosisJanuary 17, 2021
